{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
CVS Health Corp.
CVS Health Faces Weak Start with Significant Gap Down Amid Market Concerns
CVS Health Corp. opened with a significant stock price decline, contrasting with the S&P 500's stability. The company has a market capitalization of approximately USD 118.76 billion, a P/E ratio of 17.00, and a notable dividend yield. Financial metrics indicate mixed technical indicators as CVS adapts to market conditions.
CVS Health Corp. Hits New 52-Week High of $85.15
CVS Health Corp. achieved a new 52-week high of USD 85.15 on October 29, 2025, reflecting strong performance in the retail sector. The company has a market capitalization of USD 118.76 billion, a P/E ratio of 17.00, and a notable dividend yield, indicating solid financial health.
Is CVS Health Corp. overvalued or undervalued?
As of October 17, 2025, CVS Health Corp. is considered overvalued with a P/E ratio of 17 compared to the industry average of 19.83, despite a strong year-to-date stock performance of 83.83%, but it has a three-year return of -9.21%, indicating potential volatility and risk.
CVS Health Corp. Experiences Revision in Score Amidst Market Performance Evaluation
CVS Health Corp. has adjusted its valuation, showcasing a P/E ratio of 17 and a price-to-book value of 1.39. The company has a strong dividend yield and competitive returns compared to the S&P 500, although its long-term performance has been less favorable relative to the index.
Is CVS Health Corp. overvalued or undervalued?
As of October 17, 2025, CVS Health Corp. is considered overvalued with a valuation grade of "expensive," reflected in its lower P/E and EV to EBITDA ratios compared to peers, despite strong short-term returns.
Is CVS Health Corp. overvalued or undervalued?
As of October 17, 2025, CVS Health Corp. is considered overvalued with a P/E ratio of 17 compared to its peer's 19.83, despite outperforming the S&P 500 in the past year with a 29.61% return, while lagging behind in the 3-year and 10-year periods with returns of -9.21% and 38.48%, respectively.
CVS Health Corp. Hits New 52-Week High of $81.93
CVS Health Corp. achieved a new 52-week high of USD 81.93 on October 15, 2025, reflecting strong performance in the retail sector. The company has seen a 33.83% growth over the past year, significantly outperforming the S&P 500, and maintains a solid financial position with a balanced debt-to-equity ratio.
CVS Health Corp. Hits New 52-Week High at $79.94
CVS Health Corp. achieved a new 52-week high of USD 79.94 on October 14, 2025, reflecting strong performance in the retail sector. With a market cap of USD 118.76 billion, a P/E ratio of 17.00, and a dividend yield of 145.25%, the company demonstrates solid financial health and competitive valuation.
CVS Health Corp. Hits New 52-Week High of $79.67
CVS Health Corp. achieved a new 52-week high, reflecting its strong performance in the retail sector with a notable annual increase. The company, classified as large-cap, has a market capitalization of USD 118,762 million, a P/E ratio of 17.00, and a solid dividend yield, showcasing its financial strength.
CVS Health Corp. Hits New 52-Week High at $79.20
CVS Health Corp. achieved a new 52-week high of USD 79.20 on October 3, 2025, reflecting strong performance in the retail sector with a 28.55% increase over the past year. The company has a market cap of USD 118.76 billion and notable financial metrics, indicating a solid position in the industry.
CVS Health Corp. Hits New 52-Week High at $77.54
CVS Health Corp. achieved a new 52-week high of USD 77.54 on October 1, 2025, reflecting strong performance in the retail sector with a 27.52% increase over the past year. The company has a market capitalization of USD 118,762 million and a P/E ratio of 17.00.
CVS Health Corp. Hits New 52-Week High at $77.34
CVS Health Corp. achieved a new 52-week high, reflecting strong performance in the retail sector. With a market capitalization of approximately USD 118.76 billion, the company shows competitive valuation metrics, including a P/E ratio of 17.00 and a notable dividend yield, indicating a solid financial position.
CVS Health Corp. Hits New 52-Week High of $76.90
CVS Health Corp. achieved a new 52-week high, reflecting strong performance in the retail sector with a one-year growth of 26.91%. The company, with a market cap of USD 118.76 billion, features a P/E ratio of 17.00 and a dividend yield of 145.25%, showcasing its financial strength.
CVS Health Corp. Hits New 52-Week High at $76.23
CVS Health Corp. achieved a new 52-week high, reflecting strong performance in the retail sector with a notable annual increase. The company, with a market capitalization of USD 118.76 billion, demonstrates solid financial health through its P/E ratio, dividend yield, and balanced debt-to-equity ratio.
Is CVS Health Corp. technically bullish or bearish?
As of August 18, 2025, CVS Health Corp. has a bullish technical trend, supported by positive MACD and moving averages, while outperforming the S&P 500 year-to-date with a return of 65.78%.
Is CVS Health Corp. overvalued or undervalued?
As of August 15, 2025, CVS Health Corp. is considered overvalued with a P/E ratio of 17, lower than the peer average, despite a high dividend yield of 239.67%, and while it has outperformed the S&P 500 over the past year, its long-term performance has lagged behind.
Is CVS Health Corp. overvalued or undervalued?
As of May 1, 2025, CVS Health Corp. is considered overvalued with a P/E ratio of 17 and an EV to EBITDA of 9.97, despite a high dividend yield of 239.67% and a low return on equity of 8.14%, while underperforming the S&P 500.
Is CVS Health Corp. technically bullish or bearish?
As of May 12, 2025, CVS Health Corp. shows a mildly bullish trend overall, supported by daily moving averages and Bollinger Bands, despite mixed signals from the weekly MACD and KST.
Who are in the management team of CVS Health Corp.?
As of March 2022, the management team of CVS Health Corp. includes Independent Chairman David Dorman, President and CEO Larry Merlo, and several Independent Directors: Fernando Aguirre, C. David Brown, Alecia DeCoudreaux, Nancy-Ann DeParle, and Roger Farah. They oversee the company's strategic direction and operations.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
